Prosensa Holding BV of the Netherlands, which is developing an antisense oligonucleotide for Duchenne muscular dystrophy, has made a filing with the US Securities and Exchange Commission for a proposed initial public share offering. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
